The $150 Trillion Question—What Is AI’s Value In Asset Management

AI is separating asset management into firms that are getting cheaper—and firms that are getting irreplaceable. The best ones are doing both.

Nvidia, CoreWeave And Palantir Are Driving AI Forward. Which Is The Top Stock Pick?

Discover which of the three giants of the AI era, CoreWeave, Nvidia and Palantir, offers the best value for your portfolio based on growth and valuation.

EV Sales In Europe Jump With Oil Prices, But Long-Term Impact Unlikely

EV afficionados are lauding the increase in sales because of Iran war-induced increases in oil prices, but this increased demand is likely to be temporary, a report says.

Ferrari Shares Recover After Forecast Worries

After Ferrari announced first-quarter results, a pessimistic tone from management set off selling. The shares rallied when a healthy long-term outlook was established.

Speedier European Auto Deliberations Might Avoid Tariff Hike

President Trump’s threat to raise tariffs on automobiles was probably an attempt to speed up ratification of the U.S./EU trade deal negotiated in August last year.

The OpenAI Trial That Could Rewrite How AI Companies Are Built

The Musk v. Altman trial tests whether OpenAI’s for‑profit shift was legal — a ruling that could reshape how AI labs raise capital, structure governance and attract investors.

The $725 Billion AI Spending Surge Is Missing The Real Bottleneck

Big Tech’s $725 billion AI spend has a new bottleneck. Here’s what the capex explosion tells us about artificial intelligence’s real constraint.

For Bitcoin Holders, Aven’s New Credit Card Offers 7.99% Interest Rate

How to generate excitement and demand for a new credit card? A big Silicon Valley fintech is leaning into crypto.

What To Expect For Microsoft Stock’s 2026 Outlook, According To Experts

What do experts expect for Microsoft stock in 2026? Read this analysis of MSFT’s growth trends and analyst price targets for the 2026 fiscal year to get a better idea.

Do Older Adults Need Routine Colonoscopies Or Low Thyroid Drugs?

New JAMA studies examine whether routine colonoscopies and low‑dose thyroid drugs benefit older adults, raising questions about risks, costs and continued use.